We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for CRISPR (CRSP) This Earnings Season?
Read MoreHide Full Article
In the absence of any marketed product, we expect investors’ focus to be on the progress of CRISPR Therapeutics AG’s (CRSP - Free Report) pipeline candidates when the company reports second-quarter 2020 results. In the last reported quarter, the company delivered a negative earnings surprise of 5.5%.
Notably, CRISPR Therapeutics’ earnings history is mixed. This biotech company beat estimates in two of the last four quarters while missing the same twice, with the average surprise being 374.36%.
Shares of CRISPR Therapeutics have gained 48.3% so far this year compared with the industry’s increase of 5.3%.
Let’s see how things have shaped up for this announcement.
Factors to Note
CRISPR Therapeutics is a gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.
CRISPR Therapeutics has a collaboration with Vertex Pharmaceuticals (VRTX - Free Report) to develop gene therapies for treating transfusion-dependent beta thalassemia ("TDT"), sickle cell disease ("SCD"), Duchenne muscular dystrophy ("DMD") and Myotonic Dystrophy Type 1 (DM1). This collaboration generates revenues for the company in the form of milestone payments. The company received a $25 million milestone payment from Vertex Pharma in April related to the development of therapy for DM1 indications. The payment is expected to have been recorded as revenue in the second quarter.
The company is developing its lead gene-editing candidate, CTX001 in collaboration with Vertex Pharma in phase I/II studies as a treatment for TDT and SCD. Currently, the studies have not achieved enrollment target but it has been paused due to COVID-19. We expect CRISPR Therapeutics to provide an update on the enrollment status in these studies on the second-quarter earnings call.
The company is also developing immuno-oncology candidates — CAR-T cell therapies — in early-stage studies. It has two allogeneic CAR-T cell therapy candidates — CTX110 and CTX120 — targeting hematologic malignancies, including multiple myeloma. The FDA has also granted an investigational new drug application to initiate a clinical study on another allogeneic CAR-T cell therapy candidate, CTX130. The company is planning to start a study in the second half of 2020. These developments are likely to have driven operating expenses in the quarter. We expect investors to ask questions on the progress of these candidates on the earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for CRISPR Therapeutics this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (loss of 79 cents per share) and the Zacks Consensus Estimate (loss of 92 cents per share) is +13.78%.
Here are two biotech stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming release.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +4.62% and a Zacks Rank #3.
Arena Pharmaceuticals, Inc. has an Earnings ESP of +12.88% and a Zacks Rank #3.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
What's in Store for CRISPR (CRSP) This Earnings Season?
In the absence of any marketed product, we expect investors’ focus to be on the progress of CRISPR Therapeutics AG’s (CRSP - Free Report) pipeline candidates when the company reports second-quarter 2020 results. In the last reported quarter, the company delivered a negative earnings surprise of 5.5%.
Notably, CRISPR Therapeutics’ earnings history is mixed. This biotech company beat estimates in two of the last four quarters while missing the same twice, with the average surprise being 374.36%.
Shares of CRISPR Therapeutics have gained 48.3% so far this year compared with the industry’s increase of 5.3%.
Let’s see how things have shaped up for this announcement.
Factors to Note
CRISPR Therapeutics is a gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.
CRISPR Therapeutics has a collaboration with Vertex Pharmaceuticals (VRTX - Free Report) to develop gene therapies for treating transfusion-dependent beta thalassemia ("TDT"), sickle cell disease ("SCD"), Duchenne muscular dystrophy ("DMD") and Myotonic Dystrophy Type 1 (DM1). This collaboration generates revenues for the company in the form of milestone payments. The company received a $25 million milestone payment from Vertex Pharma in April related to the development of therapy for DM1 indications. The payment is expected to have been recorded as revenue in the second quarter.
The company is developing its lead gene-editing candidate, CTX001 in collaboration with Vertex Pharma in phase I/II studies as a treatment for TDT and SCD. Currently, the studies have not achieved enrollment target but it has been paused due to COVID-19. We expect CRISPR Therapeutics to provide an update on the enrollment status in these studies on the second-quarter earnings call.
The company is also developing immuno-oncology candidates — CAR-T cell therapies — in early-stage studies. It has two allogeneic CAR-T cell therapy candidates — CTX110 and CTX120 — targeting hematologic malignancies, including multiple myeloma. The FDA has also granted an investigational new drug application to initiate a clinical study on another allogeneic CAR-T cell therapy candidate, CTX130. The company is planning to start a study in the second half of 2020. These developments are likely to have driven operating expenses in the quarter. We expect investors to ask questions on the progress of these candidates on the earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for CRISPR Therapeutics this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (loss of 79 cents per share) and the Zacks Consensus Estimate (loss of 92 cents per share) is +13.78%.
Zacks Rank: CRISPR currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.
CRISPR Therapeutics AG Price and Consensus
CRISPR Therapeutics AG price-consensus-chart | CRISPR Therapeutics AG Quote
Stock That Warrant a Look
Here are two biotech stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming release.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +4.62% and a Zacks Rank #3.
Arena Pharmaceuticals, Inc. has an Earnings ESP of +12.88% and a Zacks Rank #3.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>